Adding perifosine to capecitabine does not prolong overall survival in refractory metastatic colorectal cancer, according to results of phase 3 study reported at the 2012 American Society of Clinical Oncology Annual Meeting.
Regorafenib prolongs PFS and OS in metastatic colorectal cancer that has progressed after all approved standard therapies, according to the phase 3 CORRECT trial presented at the 2012 American Society of Clinical Oncology Annual Meeting.
Weekly doses of albumin-bound paclitaxel particles lead to longer survival and are better tolerated than solvent-based paclitaxel in patients with advanced NSCLC, according to the results of a phase 3 study presented at the 2012 American Association of Clinical Oncology Annual Meeting.
Oral ridaforolimus is generally well tolerated and significantly improves PFS in metastatic sarcoma patients, according to the results of the phase 3 SUCCEED trial presented at the 2012 American Society of Clinical Oncology Annual Meeting.
Trastuzumab-naïve metastatic breast cancer patients have significantly higher clinical benefit rates and longer OS times when treated with HER2-targeted therapies, compared with patients who previously received adjuvant trastuzumab, according to a study reported at the 2012 American Society of Clinical Oncology Annual Meeting.
Adding bevacizumab to etoposide and cisplatin (BEEP) has significant anti-tumor effects in breast cancer patients with brain metastases after whole-brain radiotherapy, according to a study presented at the 2012 American Society of Clinical Oncology Annual Meeting.
Second-line treatment with axitinib showed superior PFS but not OS compared with sorafenib in metastatic renal cell carcinoma previously treated with cytokines, according to updated tiral results reported at the 2012 American Society of Clinical Oncology Annual Meeting.
Single-agent carfilzomib is efficacious in patients with relapsed and double-refractory/intolerant multiple myeloma, according to updatedtrial results presented at the 2012 American Association of Clinical Oncology Annual Meeting.
Nimotuzumab does not improve survival among newly diagnosed glioblastoma patients when added to standard temozolomide chemoradiotherapy, but warrants further study among patients with MGMT nonmethylated glioblastoma, according to a randomized multicenter phase 3 study reported at the 2012 American Society of Clinical Oncology Annual Meeting.
Experts tell Chemotherapy Advisor that new consumer-targeted cancer-screening apps may put patients at risk.
